Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index
15 Juni 2009 - 2:00PM
PR Newswire (US)
NEW YORK, June 15 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH), a medical technology company testing its
proprietary treatment method for primary and metastatic cancers to
the liver, announced today that it will be added to the
broad-market Russell 3000(R) Index when Russell Investments
reconstitutes its comprehensive set of U.S. and global equity
indexes on June 26, 2009. According to the preliminary list of
additions posted June 12, 2009 on http://www.russell.com/,
selection to the Russell 3000(R) Index means Delcath is
automatically included in the popular Russell 2000(R) Index, which
measures the performance of approximately 2,000 small-cap U.S.
securities. (Logo:
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) About
Russell: Russell Investments provides strategic advice, world-class
implementation, state-of-the-art performance benchmarks and a range
of institutional-quality investment products. Russell has $136
billion in assets under management as of March 31, 2009, and serves
individual, institutional and advisor clients in more than 40
countries. Founded in 1936, Russell is a subsidiary of The
Northwestern Mutual Life Insurance Company. About Delcath Systems,
Inc.: Delcath Systems, Inc. is a medical technology company
specializing in cancer treatment. The Company is testing a
proprietary, patented drug delivery system for the treatment of
liver cancers. Delcath's novel drug delivery platform is testing
the delivery of ultra-high doses of anti-cancer drugs to the liver
while preventing these high doses of drug from entering the
patient's bloodstream. The Company is currently enrolling patients
in Phase III and Phase II clinical studies for the treatment of
liver cancers using high doses of melphalan. The Company's
intellectual property portfolio consists of twenty-seven patents on
a worldwide basis including the U.S., Europe, Asia and Canada. For
more information, please visit the Company's website at
http://www.delcath.com/.
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGODATASOURCE:
Delcath Systems, Inc. CONTACT: Richard Taney of Delcath Systems,
Inc., +1-212-489-2100, or ; or Robin Wagge of Rubenstein
Associates, Inc., +1-212-843-8006, or , for Delcath Web Site:
http://www.delcath.com/
Copyright